MDS Pharma Services Expands Presence in Latin America with Sao Paulo Office

    KING OF PRUSSIA, PA, Jan. 28 /CNW/ - MDS Pharma Services, a leading
provider of innovative drug discovery and development solutions, has
established an office in Sao Paulo, Brazil, to provide expanded capabilities
in global clinical trial management. The new office joins nearly two dozen
other MDS Pharma Services late stage clinical trial management offices in 21
countries in Africa, Asia Pacific, Europe, Latin America and North America.
The opening of the Sao Paulo office is a clear indicator of the growing
importance of Latin America to the drug development industry and of MDS Pharma
Services' commitment to offer its clients the advantages of conducting trials
in the region.
    "Our new office in Sao Paulo is a key component of our global expansion
strategy. It allows MDS Pharma Services to provide clients access to a large
diverse pool of clinical trial participants and abundant healthcare resources,
including more than 237,000 qualified physicians and more than 46,000 health
institutions," said MDS Pharma Services President David Spaight. "Thanks to
this excellent infrastructure, clinical trials in Brazil have an impressive
track record of strong enrollment rates and good patient compliance and
retention. These are critical factors in allowing us to fulfill the MDS Pharma
Services brand promise to deliver high-quality, on-time service to clients."
    In addition to the new office in Brazil, MDS Pharma Services also offers
clinical trial monitoring services from Latin American offices in Buenos
Aires, Argentina; Santiago, Chile; Lima, Peru; and Mexico City, Mexico. Since
2002, the MDS Pharma Services team in Latin America has conducted 33 global
studies in focus areas such as oncology, metabolic disorders, cardiovascular,
vaccines and infectious diseases.
    Drug development activity has exploded in Brazil, which experienced a
1000 percent increase in clinical trials between 1995 and 2000. It is
estimated that 645 Phase I-IV clinical trials are currently taking place in
Brazil. While the incidence of heart disease, arthritis, cancer and infectious
diseases in Brazil is on par with the United States, a greater percentage of
the Brazilian population is treatment-naive, providing a major source of
potential adult and pediatric clinical trial participants who are not taking
prescription drugs that could interact or interfere with the drug being
tested. The Southern Hemisphere location is another reason to include Brazil
and other Latin American countries in multi-center trials; these countries
experience summer when it is winter in the Northern Hemisphere, allowing MDS
Pharma Services to offer its clients year-round testing of drugs for
seasonally induced conditions such as allergies and other respiratory

    About MDS Pharma Services

    MDS Pharma Services is committed to delivering quality results on time.
We offer a full spectrum of resources to meet the drug discovery and
development needs of the pharmaceutical and biotechnology industries. With
numerous facilities strategically located around the world, we apply advanced
scientific and technological expertise throughout the drug discovery and
development process - from lead optimization, pre-IND research, early clinical
research (bioequivalence, phases I-IIa) and bioanalysis through to global
clinical development (phases IIb-IV), central lab and centralized cardiac
services. For more information, visit our website at
    MDS Pharma Services is a business unit of MDS Inc. (TSX: MDS; NYSE:   MDZ),
a global life sciences company that provides market-leading products and
services that our customers need for the development of drugs and diagnosis
and treatment of disease. We are a leading global provider of pharmaceutical
contract research, medical isotopes for molecular imaging, radiotherapeutics,
and analytical instruments. MDS has more than 5,500 highly skilled people in
28 countries. Find out more at or by calling 1-888-MDS-7222,
24 hours a day.

    Source data - website

    (*) 645 Phase I-IV studies currently taking place in Brazil

For further information:

For further information: For Investors, Sharon Mathers, (416) 675-6777
ext. 34721,; For Media, Charlene McGrady, (610)
239-7900 ext. 231,

Organization Profile

Nordion Inc.

More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890